Amivantamab Shows Tumor Response in 43 of 102 Patients With Advanced Head and Neck Cancer
An 11-nation trial of the Johnson & Johnson drug showed tumor shrinkage in more than a third of patients whose disease had returned or spread. Median survival reached 12.5 months after treatment began.
The GuardianTumors shrank or disappeared in 43 of 102 patients with head and neck cancer who received the Johnson & Johnson drug amivantamab after prior treatments failed. The changes appeared within weeks of the first injection. Fifteen patients experienced complete disappearance of their tumors and 28 recorded measurable shrinkage.
The trial spanned 11 countries and enrolled patients whose disease had either spread or returned. 5 months after starting amivantamab. Head and neck cancer is the sixth most common cancer worldwide.
Kevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research in London, said the responses were “unprecedentedly strong” in patients resistant to both chemotherapy and immunotherapy. ” The trial results will be presented Sunday at the American Society of Clinical Oncology annual meeting in Chicago.
Amivantamab targets a protein that helps tumors grow, blocks a pathway cancer cells use to resist treatment, and directs the immune system toward the tumor.
The same mechanism produced comparable results in certain lung cancers. Carl Walsh, 56, was diagnosed with tongue cancer in May 2024 and joined the trial in July 2025. ” Before treatment he struggled to speak and eat because of swelling and pain.
Amivantamab is currently under study in roughly 60 trials, most focused on lung cancer, with additional testing in colorectal, brain, and gastric cancers.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
nypost.comWHO Reports Five Recoveries From Rare Ebola Strain in Congo and Uganda
The World Health Organization said five people have recovered from the Bundibugyo strain despite the absence of approved treatments or vaccines. At least 906 suspected cases and 223 deaths have been reported across the affected region.
citizen.co.zaEbola Outbreak in Eastern Congo Reaches 906 Suspected Cases
WHO Director-General Tedros Adhanom Ghebreyesus arrived in Bunia on May 30 to assess the response to a Bundibugyo virus outbreak that has killed 223 people. Officials reported cases spreading to North Kivu and South Kivu, while Uganda confirmed nine infections.
France 24Zambia’s Kabwe Residents Sue Mining Company Over Lead Contamination
Children in Kabwe, Zambia, show blood lead levels above World Health Organization limits after decades of mining. An estimated 140,000 women and children have joined a class-action lawsuit against Anglo American South Africa Limited.